HC Wainwright & Co. Initiates Coverage On Heron Therapeutics with Buy Rating, Announces Price Target of $6

Benzinga · 06/09 11:29
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Heron Therapeutics (NASDAQ:HRTX) with a Buy rating and announces Price Target of $6.